Eriberto Natali, Jana Hersch, Christoph Freiberg, Stephan Steigele
{"title":"通过数据分析和工作流管理的统一数字平台推进大分子发现。","authors":"Eriberto Natali, Jana Hersch, Christoph Freiberg, Stephan Steigele","doi":"10.1080/19420862.2025.2555346","DOIUrl":null,"url":null,"abstract":"<p><p>The repertoire of large-molecule treatments continues to expand, resulting in diverse discovery and development workflows. This diversity yields a proliferation of software solutions and procedures for molecule registration, material tracking, experiment planning, data analytics, quality control, data sharing, and decision-making. Contrasting with this manual, labor intensive, and error-prone approach, we introduce the concept of a transformative solution: an integrated platform that translates this complexity into a harmonized, open architecture encompassing all workflows and hardware systems, covering the discovery process up to developability assessment. The benefits and complexities of such a platform are evident in examples spanning different use cases and maturity levels, such as developing multi-specific antibodies and antibody-drug conjugates using shared workflows or incorporating artificial intelligence for predictive and generative tasks. This review outlines state-of-the-art concepts behind a digital platform for automating and streamlining the discovery of new large-molecule treatments.</p>","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2555346"},"PeriodicalIF":7.3000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439557/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advancing large-molecule discovery with a unified digital platform for data analysis and workflow management.\",\"authors\":\"Eriberto Natali, Jana Hersch, Christoph Freiberg, Stephan Steigele\",\"doi\":\"10.1080/19420862.2025.2555346\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The repertoire of large-molecule treatments continues to expand, resulting in diverse discovery and development workflows. This diversity yields a proliferation of software solutions and procedures for molecule registration, material tracking, experiment planning, data analytics, quality control, data sharing, and decision-making. Contrasting with this manual, labor intensive, and error-prone approach, we introduce the concept of a transformative solution: an integrated platform that translates this complexity into a harmonized, open architecture encompassing all workflows and hardware systems, covering the discovery process up to developability assessment. The benefits and complexities of such a platform are evident in examples spanning different use cases and maturity levels, such as developing multi-specific antibodies and antibody-drug conjugates using shared workflows or incorporating artificial intelligence for predictive and generative tasks. This review outlines state-of-the-art concepts behind a digital platform for automating and streamlining the discovery of new large-molecule treatments.</p>\",\"PeriodicalId\":18206,\"journal\":{\"name\":\"mAbs\",\"volume\":\"17 1\",\"pages\":\"2555346\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439557/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"mAbs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/19420862.2025.2555346\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2025.2555346","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Advancing large-molecule discovery with a unified digital platform for data analysis and workflow management.
The repertoire of large-molecule treatments continues to expand, resulting in diverse discovery and development workflows. This diversity yields a proliferation of software solutions and procedures for molecule registration, material tracking, experiment planning, data analytics, quality control, data sharing, and decision-making. Contrasting with this manual, labor intensive, and error-prone approach, we introduce the concept of a transformative solution: an integrated platform that translates this complexity into a harmonized, open architecture encompassing all workflows and hardware systems, covering the discovery process up to developability assessment. The benefits and complexities of such a platform are evident in examples spanning different use cases and maturity levels, such as developing multi-specific antibodies and antibody-drug conjugates using shared workflows or incorporating artificial intelligence for predictive and generative tasks. This review outlines state-of-the-art concepts behind a digital platform for automating and streamlining the discovery of new large-molecule treatments.
期刊介绍:
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.